Thousands of NHS patients could gain access to life-changing medicines months earlier under a series of pioneering pilot programmes announced by the Government, marking what ministers describe as a significant step towards faster, fairer access to innovative treatments while reinforcing the UK’s position as a global life sciences leader.
The pilots, developed through a joint taskforce involving government, the NHS, the pharmaceutical industry, and patient organisations, will begin testing new approaches to medicines pricing, adoption, and access from as early as September. The initiative also delivers on commitments made under the UK-US pharmaceutical arrangement to encourage greater investment in innovative medicines.
The announcement comes just months after changes to the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold were introduced in April, changes that have already resulted in nine additional medicines being approved for NHS patients in England and Wales.
Those newly approved treatments cover a range of serious conditions, including blood disorders, autoimmune diseases, and several forms of cancer, among them brain tumours affecting young children, and advanced stomach cancers where treatment options have previously been limited.
Together, ministers say the reforms could offer thousands of patients access to potentially life-changing therapies while paving the way for even more medicines to become available in future.
Faster treatment for patients
One of the headline pilots will focus on ensuring patients receive innovative medicines more quickly once treatments have met the required standards for safety, quality, and clinical effectiveness. This includes therapies for rare diseases, where delays can have particularly serious consequences.
Health and Social Care Secretary, James Murray said the reforms are designed to ensure patients benefit from medical innovation without unnecessary delays.
“When a new medicine is proven to work, patients shouldn’t have to wait.”
He added:
“These pilots are designed to give life-changing treatments to NHS patients faster and more fairly than ever before, while ensuring taxpayers continue to get value for money.
“That’s good for patients, good for the NHS, and good for Britain’s place as a world leader in life sciences.”
As the new arrangements become established, NICE expects they could enable up to five additional medicines to be approved every year compared with previous arrangements, building on its existing record of approving more than 90% of medicines it assesses.
Supporting innovation and economic growth
Beyond improving patient access, the pilots also reflect the Government’s wider industrial strategy to strengthen one of the UK’s most successful high-value sectors.
Pharmaceuticals remain one of Britain’s globally competitive industries, supporting highly skilled jobs across research, manufacturing, and commercial operations.
The Government has committed to doubling spending on innovative medicines from 0.3% to 0.6% of GDP over the next decade, a move intended to stimulate investment while supporting the ambitions set out in both the 10 Year Health Plan for England and the forthcoming Life Sciences Sector Plan.
Among the additional pilots being introduced are a new approach to recognising the wider economic benefits of medicines, including helping people return to work following treatment, alongside mechanisms allowing pharmaceutical companies to co-invest in patient screening, testing, and wider care pathways.
Dedicated regional funding will also be introduced to help local NHS systems accelerate access to priority medicines and improve uptake of innovative treatments across England.
Science Minister, Lord Vallance said the UK must ensure breakthroughs in medicine reach patients as quickly as possible.
“We are in an era of rapid advances in new preventative measures, treatments and even cures. We have a responsibility to get the most important of these into the hands of doctors and patients as quickly as possible. These pilots will help us do exactly that.”
He added:
“Improving outcomes for patients, giving doctors more tools to treat and beat disease, and delivering the innovations that drive our ambition to become the leading life sciences country in Europe – that’s how we’re working to deliver an NHS which is fit for the future.”
The NHS pilots aim to help patients access innovative medicines more quickly, while supporting stronger life sciences investment across the UK.
Industry welcomes collaborative approach
The pharmaceutical industry has broadly welcomed the measures, describing them as an important milestone in improving access to medicines while boosting confidence in the UK’s investment environment.
Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), Richard Torbett said:
“The measures announced today are the product of intensive and focused effort between industry and government to ensure NHS patients get the medicines they need.”
He continued:
“While there is more work to be done, today’s news represents an important step on the path to achieving our shared goal of making the UK a world-leading environment for patient access and life sciences investment.
“We have already seen industry respond positively to the Government’s commitment earlier this year to increase investment in innovative medicines. I hope that these delivery measures continue to build investor confidence and enable us to make further progress together.”
The announcement follows months of collaboration between government and industry representatives through a dedicated 10-week taskforce established to identify practical solutions to long-standing barriers affecting the adoption of innovative medicines.
Patients and charities highlight benefits for rare diseases
Patient organisations have also welcomed the focus on reducing delays, particularly for people living with life-threatening or rare conditions where access to treatment can be critical.
Chair of the Charity Medicines Access Coalition (CMAC), Dr Scott Purdon described the announcement as “welcome news.”
He said:
“We are especially pleased to see a focus on faster, fairer access to treatments. For people living with life-threatening or life-limiting conditions every day matters; delays aren’t just frustrating, they can shorten lives and worsen quality of life.”
He also praised the involvement of patient groups in designing the pilots.
“The inclusion of patient expertise and representation in shaping the pilots is encouraging, showing a system that is starting to listen and act on what matters most: equitable outcomes for patients.”
Chief Executive of Genetic Alliance UK, Nick Meade, and every day people’s conditions are progressing past the point where treatments can be given.”
He added:
“Getting treatments into managed access programmes without waiting for a full NICE assessment could mean people get treated months earlier – this time saved has the real potential to save lives.”
Mr Meade said the pilots could also help address longstanding inequalities affecting treatments for rare diseases.
“These pilots could level the playing field for rare condition treatments, overcoming some of the fundamental inequities they face in our current system due to their intrinsic low-evidence bases. We welcome this challenge being addressed and look forward to seeing how this works in practice.”
With the first pilot schemes expected to begin later this year, the Government hopes the new approach will improve patient outcomes while demonstrating that faster access to innovation can go hand in hand with supporting investment, economic growth, and the long-term sustainability of the NHS.
Final Thought:
For UK Healthcare and Life Sciences Innovation (UKHLSI), the test of these reforms will be whether faster approval translates into faster and more consistent uptake across the NHS. Accelerated access matters only if local systems have the funding, diagnostics, workforce capacity, data infrastructure, and clinical pathways needed to deliver innovation at scale.
The pilots are therefore an important opportunity to close the gap between national ambition and frontline adoption, ensuring that patients benefit from new medicines not only in principle, but in practice. If government, industry, NICE, and the NHS can maintain this collaborative approach, the UK has a real opportunity to show that improved patient outcomes, stronger life sciences investment, and better value for the health service can be advanced together.
To find out more about UKHLSI’s work to accelerate the uptake of innovation into UK healthcare and life sciences, contact Chief Executive, Jo Bekis at enquiries@ukhlsi.co.uk.